Lilly and the Medicare GLP-1 bridge program

When the Trump administration struck voluntary pricing agreements with Eli Lilly and Novo Nordisk in early 2026, the deal came with a concrete payoff for Medicare beneficiaries: access to covered GLP-1 weight-loss drugs at a $50 monthly copay through a new temporary program called the Medicare GLP-1 Bridge^[1]. The program launched July 1, 2026, and is scheduled to run through December 2027. Now, with Q2 2026 financial results on the table, analysts are starting to model what the bridge program means for Lilly's top line.

What the bridge program actually covers

The Medicare GLP-1 Bridge is a Section 402 demonstration program, which means it sidesteps the longstanding statutory ban on Medicare Part D covering weight-loss drugs without repealing it^[1]. Manufacturers agreed to a negotiated net price of $245 per 30-day supply. Beneficiaries pay $50 per month, and that copay does not count toward Part D deductibles or annual out-of-pocket caps.

Covered drugs include Mounjaro, Ozempic, Rybelsus, Wegovy, and Zepbound (KwikPen formulation only). That covers both of Lilly's major incretin products and Novo Nordisk's semaglutide portfolio. Eligibility requires a qualifying BMI and a provider attestation that the drug is for weight reduction and maintenance, not another indication. Low-Income Subsidy enrollees receive no additional cost-sharing help under the current program structure, which KFF analysts flag as a potential equity gap^[1].

The MFN deal that made it possible

The bridge program sits inside a broader set of voluntary arrangements Lilly finalised with the US government in Q1 2026. Per Lilly's own 10-Q filing with the SEC, the company agreed to lower Medicaid and certain other drug prices and 'to launch new medicines with a more balanced pricing approach across developed nations'^[2]. Lilly also committed to continuing engagement with the Centers for Medicare and Medicaid Services on long-term Medicare access to obesity medicines beyond the bridge's December 2027 expiry.

The broader pricing architecture is visible on TrumpRx.gov, the administration's official Most-Favored-Nation pricing portal, which lists MFN prices for GLP-1 drugs: Zepbound at $299/month (down from $1,087), Wegovy at $149 to $199/month (down from $1,349), and Ozempic at $199/month (down from $1,028)^[3]. The bridge program's $50 copay is a separate, Medicare-specific access layer on top of these MFN list-price reductions.

What Lilly's Q2 numbers show

Lilly's Q2 2026 results, filed with the SEC on August 5, show the scale of the incretin business that the bridge program will feed into. Mounjaro generated $9.94 billion in Q2 2026 revenue alone, a 91% increase on the same half-year period in 2025. Zepbound added $4.93 billion in the same quarter, up 60% year-on-year^[4]. Combined, the two tirzepatide products brought in just under $15 billion in a single quarter. Total company revenue for Q2 2026 was $22.97 billion.

Lilly noted in its Q2 filing that Mounjaro and Zepbound revenue increases were 'driven primarily by increased volume, partially offset by lower realized prices'^[4]. The price offset reflects the voluntary agreement terms. The volume gain is what analysts are mapping against the bridge program.

The analyst read-through

The bridge program launched July 1, 2026. At the time Lilly's Q1 10-Q was filed in April 2026, the company wrote that 'the uptake from this expanded access is unknown'^[2]. That was an honest forward-looking caveat: the bridge had not started yet and no enrollment data existed. Q3 2026 results, expected in late October, will be the first financial reporting period that captures a full quarter of bridge activity.

Analysts covering Lilly have focused on two numbers from the bridge's design. First, the eligible population: Medicare covers roughly 67 million Americans, and obesity prevalence in that age group runs high. Even modest bridge uptake across that base translates to material unit volume. Second, the net price per unit ($245 negotiated versus list prices well above $1,000) is lower than Lilly's current US average realised price, but the incremental volume from previously uncovered patients could more than offset the price difference.

The policy risk analysts are watching

The bridge is a demonstration program, not a statute. It runs on Section 402 authority and can be ended, modified, or allowed to expire by any administration without Congressional action^[1]. The BALANCE Part D model, which was meant to create a more durable Medicare GLP-1 benefit through private Part D plans, was delayed indefinitely after insurers declined to participate at scale. That makes the bridge the only active Medicare access route for weight-loss GLP-1s through at least December 2027.

The Treat and Reduce Obesity Act, which would create a permanent Part D benefit for obesity medications, has been introduced in multiple Congressional sessions without passing. Until that legislation advances, Lilly's Medicare bridge exposure rests on a demonstration program authority rather than a standing entitlement. For the underlying legal framework, the relevant statute is 42 USC 1396r-8(d)(2), which still prohibits Part D from covering drugs 'when used for anorexia, weight loss, or weight gain'^[5].

What we do not yet know

CMS has not published bridge program enrollment numbers. Lilly has not disclosed bridge-specific volume data. A FiercePharma report from early September 2026 cited analyst estimates for annualised Lilly revenue from the program, but those projections depend on assumptions about uptake rates, adherence, and eligibility attestation compliance that will only be testable once CMS releases utilization data. The first real signal will be Lilly's Q3 2026 guidance, which will include the first full quarter of bridge prescriptions.

For now, the structural picture is clear: Lilly has a product (tirzepatide, sold as both Mounjaro and Zepbound) with proven efficacy and an enormous newly accessible population. Whether the access translates into blockbuster bridge-specific sales is a utilization question the company will answer in its next earnings call.